T-helper cell type 2 (Th2) cytokine production pathway (Th2 pathway)

The T-helper cell type 2 (Th2) cytokine production pathway is a fundamental arm of the adaptive immune system responsible for coordinating Type 2 inflammation (StatPearls, 2023). It is characterized by the secretion of key effector cytokines, including Interleukin-4 (IL-4), Interleukin-5 (IL-5), and Interleukin-13 (IL-13), primarily by CD4+ Th2 cells, though Type 2 innate lymphoid cells (ILC2s) also contribute significantly (PubMed, PMID: 29385444). These cytokines drive essential biological processes such as B-cell isotype switching to IgE, eosinophil maturation and recruitment, and goblet cell hyperplasia (Nature Reviews Immunology, 2018). While this pathway is evolutionarily designed to combat helminth parasites, its dysregulation is a central driver of allergic and atopic diseases, including asthma and atopic dermatitis (NIH, 2022). Modern therapeutic strategies focus on biologics that selectively inhibit these cytokines or their receptors to alleviate chronic inflammation in Th2-high patient endotypes (Journal of Allergy and Clinical Immunology, 2020).

Other names

Type 2 immune responseTh2 signaling pathwayTh2-mediated inflammationType 2 cytokine pathway

Drugs targeting this pathway typically utilize monoclonal antibodies to neutralize specific cytokines (e.g., IL-5) or block their receptors (e.g., IL-4Rα), thereby preventing the activation of downstream signaling molecules like STAT6 and GATA3, which are necessary for the expression of pro-inflammatory genes (PubMed, PMID: 30124222).